中国医院用药评价与分析2025，Vol.25Issue(8)：980-983,988,5.DOI:10.14009/j.issn.1672-2124.2025.08.017
消癥丸治疗乳腺增生、子宫肌瘤的临床综合评价
Clinical Comprehensive Evaluation of Xiaozheng Pills in the Treatment of Hyperplasia of Mammary Gland and Hysteromyoma
摘要
Abstract
OBJECTIVE:To evaluate the clinical comprehensive value of Xiaozheng pills in the treatment of hyperplasia of mammary gland and hysteromyoma.METHODS:Taking Xiaozheng pills as the evaluation object and the Guidelines for Clinical Comprehensive Evaluation of Chinese Patent Medicines(2022 Trial Version)as the criterion,comprehensive evaluation was carried out around six dimensions of effectiveness,safety,economy,inheritance and innovation,suitability and accessibility by sorting out literature and other relevant materials.RESULTS:In terms of effectiveness,Xiaozheng pills could improve the total effective rate of hyperplasia of mammary gland and hysteromyoma.In terms of safety,Xiaozheng pills had low incidence of adverse drug reactions,mainly for gastrointestinal tract and skin reactions.In terms of economy,the incremental cost-effectiveness of Xiaozheng pills was superior to that of the control drugs such as Rupixiao capsules.In terms of inheritance and innovation,Xiaozheng pills had obtained national second-class protected varieties and three invention patents.In terms of suitability,Xiaozheng pills was easy to use and the drug instructions met the current regulations.In terms of accessibility,Xiaozheng pills was available for sale in multiple provinces,municipalities directly under the Central Government and autonomous regions,and the raw materials were consistently available.CONCLUSIONS:Xiaozheng pills demonstrates multi-dimensional advantages of"efficacy,safety and economy"in the treatment of hyperplasia of mammary gland and hysteromyoma,with significant clinical comprehensive value.Future large-scale real-world studies and long-term cost-utility modeling are recommended to strengthen evidence quality and inform clinical decision-making.关键词
消癥丸/乳腺增生/子宫肌瘤/临床综合评价Key words
Xiaozheng pills/Hyperplasia of mammary gland/Hysteromyoma/Clinical comprehensive evaluation分类
医药卫生引用本文复制引用
郭媛媛,冷怡林,徐阳,郭丹丹,曹俊岭,何婷,李慧,李佳怡,张然,马丽娜,顾媛媛,赵薇,李旨君,郑长辉..消癥丸治疗乳腺增生、子宫肌瘤的临床综合评价[J].中国医院用药评价与分析,2025,25(8):980-983,988,5.基金项目
北京市中医管理局-中药临床应用评价项目(2022) （2022）
河南省临床中药学重点学科建设项目(No.豫卫中医药科教[2024]1号) （No.豫卫中医药科教[2024]1号）
